Sign In
Buy VNDA
$6.09
-0.0400 (-0.653%)
At Close: Jun 03, 2026
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
05:13pm, Wednesday, 04'th Sep 2024
WASHINGTON , Sept. 4, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the H.C.
Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference
04:30pm, Thursday, 29'th Aug 2024
WASHINGTON , Aug. 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Wells Fargo 2024 Healthcare Conference in Boston o
Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over
02:19pm, Thursday, 08'th Aug 2024
Vanda Pharmaceuticals Inc. received and then refused two takeover bids that were well above current market prices. Vanda currently trades below net cash despite having significant revenue and operatio
Vanda Pharmaceuticals Inc. (VNDA) Q2 2024 Earnings Call Transcript
01:14pm, Friday, 02'nd Aug 2024
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Kevin Moran - Chief Financial Officer Mihael Polymeropoulos - President, Chief
Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results
04:01pm, Wednesday, 31'st Jul 2024
Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023 Financial Guidance reinstated for Full Year 2024 Fanapt® approved for the acu
Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
09:19am, Friday, 26'th Jul 2024
Conference Call and Webcast to Follow WASHINGTON , July 26, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2024 o
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex
08:01am, Monday, 01'st Jul 2024
WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of Delaware (the "Court") denied the motions f
Future Pak withdraws offer to buy Vanda Pharmaceuticals
06:27pm, Wednesday, 26'th Jun 2024
Contract manufacturer Future Pak said on Wednesday it has withdrawn its offer to acquire Vanda Pharmaceuticals , citing non-engagement from the U.S. drugmaker.
Future Pak Withdraws Proposal to Purchase Vanda Pharmaceuticals Inc.
05:37pm, Wednesday, 26'th Jun 2024
WIXOM, Mich.--(BUSINESS WIRE)--Consistent with the position indicated in its June 13, 2024 letter to Vanda Pharmaceuticals (“Vanda”), Future Pak LLC and its affiliates ("Future Pak") today announc
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
05:29am, Thursday, 20'th Jun 2024
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.
Vanda rejects Future Pak and Cycle Pharma's takeover offers
09:40pm, Wednesday, 19'th Jun 2024
Vanda Pharmaceuticals said on Wednesday that it has rejected takeover offers from UK-based Cycle Pharmaceutical and a revised bid from contract manufacturer Future Pak, adding that both offers underva
WASHINGTON , June 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board"), following careful review and consulta
Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
09:59pm, Monday, 17'th Jun 2024
Vanda Pharmaceuticals' portfolio includes FDA-approved Hetlioz for sleep disorders, Fanapt for schizophrenia and bipolar I disorder, and Ponvory for multiple sclerosis. VNDA's upcoming pipeline featur
Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%
09:00pm, Thursday, 13'th Jun 2024
The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size is Expected to Reach USD 6.47 Billion by 2033, according to a research report
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
10:02am, Thursday, 13'th Jun 2024
No Shareholder Action Required at This Time WASHINGTON , June 13, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received a revis
